Skye Bioscience Receives Nasdaq Delisting Notice for Failing Minimum Bid Price Rule

summarizeSummary

Skye Bioscience, Inc. received a Nasdaq deficiency letter for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day period to regain compliance and highlighting ongoing financial challenges.

check_boxKey Events

• Nasdaq Deficiency Letter Received

  Skye Bioscience, Inc. received a deficiency letter from Nasdaq on March 17, 2026, notifying the company of non-compliance with the minimum bid price rule.

• Failure to Meet Minimum Bid Price

  The company's common stock traded below the required $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).

• 180-Day Compliance Period

  Skye Bioscience has 180 calendar days, until September 14, 2026, to regain compliance. Options include achieving a $1.00 closing bid price for 10 consecutive days or executing a reverse stock split.

• Follows Prior Delisting Risk Disclosure

  This formal notice directly follows the company's 10-K filing on March 10, 2026, which explicitly warned of NASDAQ delisting risk due to its critical financial state and going concern warning.

auto_awesomeAnalysis

Skye Bioscience, Inc. received an official deficiency letter from Nasdaq due to its common stock trading below the $1.00 minimum bid price for 30 consecutive business days. This formal notice confirms a risk previously highlighted in the company's 10-K filing on March 10, 2026, which warned of a going concern and Nasdaq delisting risk. The company now has 180 calendar days, until September 14, 2026, to regain compliance. Failure to do so could lead to delisting, although a second 180-day period may be available under certain conditions. The company's options include achieving a $1.00 bid price for 10 consecutive days or implementing a reverse stock split. This event underscores the severe financial challenges the company faces, as previously indicated by its going concern warning and significant net losses.